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Abstract
Background: Orthodox dentistry has undergone significant changes in recent times with the introduction of
various omics and molecular targeted therapies both at the experimental/trial and clinical implementation level.
Although, significant milestones have been achieved in the molecular dentistry field in the past decade, there
remains a dearth of application of phytopharmacological innovation in personalized and targeted therapies for
dental diseases.
Main body: From time immemorial, plant products have long been an integral aspect of dental practice ranging
from chewing sticks/herbal kinds of toothpaste to dental/impression materials. The current era of precision
medicine seeks to apply a multipronged molecular and bio-computational approaches to solve fundamental
medical problems that have hitherto remained difficult. Remarkable changes in the molecular/omics era, have
transformed empirical therapies into personalized/individualized ones. Furthermore, the combinatorial application
and the widespread introduction of high-throughput molecular tools such as pharmacogenomics,
phytopharmacology, metabolomics, mathematical modelling, and genetic engineering inter alia, has tremendously
improved the diagnostic and therapeutic landscape of medicine. Additionally, the variable molecular epidemiology
of diseases among different population and emerging molecular evidence warrants the use of customized novel
theranostic techniques. Unfortunately, the footprint of such emerging application is sparse in dental diseases such
as maxillofacial cancers.
Conclusion: Hence, this review seeks to evaluate the potential application of phytopharmacological approaches to
head and neck cancers in a resource-limited environment, such as Africa.
Keywords: Phytopharmacology, Cancer, Dental pathology, Molecular mechanism, Dentistry, Structural biology,
Phytodentistry
Introduction
Healing with plants is as old as mankind itself. The link
between man and his quest for treatments in nature
dates back to ancient times when anecdotal evidence
was garnered from monuments, written documents, and
even original plant medicines [1]. Plants have been used
for prophylaxis and healing of diverse diseases before
the advent of iatrochemistry in the sixteenth century [2].
This has been particularly showcased in Africa since an-
cient times, with the widespread integration of medicinal
plants in the indigenous healthcare practices.
Africa is known as the cradle of mankind and it pos-
sess a rich cultural and biological diversity [3]. Phyto-
pharmacology and phytomedicine has been in Africa for
centuries and is considered the most widely used
method for healing practices. Phytomedicine in Africa
employs a holistic approach which considers both the
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healing of the mind and the body. The psychological
basis of diseases is first addressed before medical regi-
mens (typically-derived) are provided to cure the disease
[4]. There are 3 major reasons why there is a sustained
interest in African phytomedicine, viz: poor access to
western allopathic medicines due to lack of financial re-
sources, manpower and health infrastructure; lack of ef-
ficacious modern medicine for some illnesses which are
typical to Africa; and the rich diversity of the African
flora and fauna [5]. In addition, detrimental side effects
and reducing efficacy of synthetic western drug have re-
awakened the attention of researchers globally to natural
medicine (particularly from Africa), in recent times [6].
Such efforts have revealed a plethora of African plants
that have potent pharmacological effects and hence are
good candidates for the development of lead compounds
in the drug discovery pipelines.
Phytomedicine is globally sought after as a means pri-
mary healthcare provision for ca. 3.5–4.0 billion people,
and a significant percentage of this involves the use of
plant-derived decoction and medicines [7]. More so,
using medicinal plants has been the most commonly
practised traditional medicine system across the African
continent. Medicinal plants are readily accessible health
resources for many African communities [8]; and they
are often more preferred over conventional medicine [9].
Information, treatment and counselling, garnered from
traditional healers are presented to patients and their
families in a more indigenous and cultural manner [10].
As a matter of fact, Africa is highly endowed with plant
biodiversity constituted by ca. 40,000 to 45,000 plant
species that can be potentially developed; and close to
5000 of these are currently medically applied according
to pharmacopoeia information [11, 12]. The fact that Af-
rica is situated tropically with subtropical climate favours
an adaptive accumulation of secondary plant metabolites
[13]. Strong ultraviolet rays from tropical sunlight and
pathogenic microbes, such as fungi, bacteria, and viruses
are additional factors that promote the accumulation of
plant chemopreventive in relatively higher concentra-
tions compared to northern hemisphere flora. A Dorste-
nia (Moraceae) study reported Dorstenia mannii Hook.f,
which is perennial to the tropical central African rain
forest to contain more biologically active components as
compared to other related species [14].
Hence, accurate documentation of indigenous African
plant medicinal systems has become essential, to miti-
gate the continuous erosional and anthropogenic loss of
natural habitats. It has been reported that even though
Africa has close to 216 million hectares of forest, she un-
fortunately also has one of the highest levels of deforest-
ation globally (ca. of 1% per annum) [15]. Against this
backdrop, limited healthcare resources and high burden
of head and neck cancer [16] warrants a more extensive
use of phytopharmacological compounds in the African
dental setting. This review focuses mainly on the poten-
tial beneficial effect of medicinal plant bioactive com-
pounds, for the management of cancers (particularly
head and neck), in the context of Africa.
Benefits and direction of phytopharmacology in
the African setting
Nature is the most effective source of naturally occur-
ring herbs that are a reservoir of pharmacologically ac-
tive phytochemicals and phytomedicine. Their easy
accessibility, affordability, safety and efficacy have hugely
culminated in their success against some severe diseases
and reliability among the users [17]. Indeed, conven-
tional medicine has its roots in medicinal plants, and it
is likely that many novel remedies will still be developed
and commercialized in the future from the African bio-
diversity, as it has been till now, by following the leads
provided by traditional knowledge and experiences [4,
12]. Over the last decade in Africa, there has been enor-
mous rise in medicinal plants-derived products in terms
of interest and use [10]. Prior to this time, what used to
be the exclusive domain of health food and speciality
stores has now gained considerable popularity into the
mainstream market as evident by their impressive sale at
some of the major retail outlets, their publicity, and ad-
vertising in the media, and due to the entry of various
pharmaceutical giants in the area of phytomedicines.
Also, despite that dosage standardization, exact mechan-
ism of action and safety issues could still be identified as
factors militating against the use of many of the medi-
cinal plants within the African setting and beyond, the
World Health Organization (WHO, 2000) has encour-
aged African member states to promote and integrate
traditional medical practices in their health system.
Unlike the first and second generation phytopharma-
cological advancements in Africa, the third and indeed
the current generation is poised to encourage formula-
tions based on well-controlled double-blind clinical and
toxicological studies to improve the quality, stability,
safety and efficacy of such formulations [8]. Also, con-
trary to the argument that appreciation of phytomedi-
cine in Africa is linked to cultural and economic
reasons, emerging evidence from clinical and experimen-
tal data strongly suggests their therapeutic efficacy
against several diseases including diabetes, malaria,
sickle-cell anaemia, Human Immunodeficiency Virus/
Acquired Immune Deficiency Syndrome (HIV/AIDS),
cancer, dental disease, stroke, ulceration, Alzheimer’s
disease, Parkinson’s disease, Huntington’s disease, and
microbial infections etc. [6, 10, 15, 18–23]. Furthermore,
through appreciation of phytopharmacology, many Afri-
can phytomedicines have become well known in the
international markets and several of them including a
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Cameroonian plant (Ancistrocladus abbreivatus) with
anti-HIV/AIDS potential, Elaeis guineensis, Agava sisa-
lana, Tamarindus indica, Zingiber officinale, Capsicum
annum, Phytostigma venenosum, Catharantus roseus,
Rauvolfia vomitoria, Chrysanthemum cinerariifolium, and
Prunus africana etc. with diverse pharmacological activ-
ities are exported to other parts of the world and contrib-
uting to the economic development of the region [8].
In spite of the tremendous efforts of African phyto-
pharmacologists to decipher African ailments and prof-
fer lasting solutions, gaps still exist and there is a need
for a more holistic, rational, and generally acceptable
strategy to explain the efficacy of medicinal plants and
their mechanisms of action. In view of this, the concept
of “-omics” (metabolomics, proteomics, transcriptomics,
and genomics etc.) as currently being explored, could
find relevance and may provide useful data supporting
the efficacy of phytotherapy. Ultimately, this will annihi-
late the mainstream issues against the advancement of
phytopharmacology in Africa and making it one of the
focal contributors to research advancement and eco-
nomic development of the continent. Research in this
direction holds promising scope for discovering precise
and novel therapeutic products in Africa and beyond.
Phytopharmacology and head and neck cancer
Over the years, cancer continues to impose a heavy bur-
den on public health and presents a challenge to science.
Globally, cancer is a leading cause of death; it is believed
that the growth and aging of the population will increase
cancer burden, especially in Africa, Asia, Central and
South American, where approximately 70% of the
world’s population resides [24, 25]. This disease has been
labelled as a global menace and kills more people than
AIDS, tuberculosis and malaria combined [26, 27]. As
documented by Ferlay et al., [25], head and neck cancer
accounts for over 600,000 cases yearly, with 40%–50%
mortality. In fact, over half of all sufferers will eventually
die of the disease [28]. The tumours arise in the epithe-
lial cells of the mucosal linings of the oral cavity, nasal
cavity, oropharynx, pharynx and larynx, most of which
are squamous cell carcinoma of the head and neck
(SCCHN) [29]. In addition to the synergistic effect of to-
bacco and alcohol, which is the most important risk fac-
tors for SCCHN, infection with human papillomavirus
(HPV) has also been implicated in the pathogenesis of
SCCHN [30]. Besides these exogenous risk factors, Fan-
coni anaemia and a more general genetic susceptibility
may cause SCCHN [30, 31]. The choice of treatment of
SCCHN is largely dependent on the stage and location
of tumour. The stage of the tumour is determined by
the extent of the tumour, presence of lymph node me-
tastases and distant metastases. More so, correct staging
with the aid of computed tomography (CT) or magnetic
resonance imaging (MRI) by a head and neck surgeon is
of paramount importance in therapeutic decision mak-
ing [29]. Current treatment options include surgery and
radiotherapy. However, recurrent and metastatic cancer
is generally untreatable. As reviewed by Forastiere et al
[32], great strides have been made in the treatment of
head and neck cancer, but existing treatment options are
still faced with one or more challenges. Noteworthy is
the invasiveness of surgical methods and chemothera-
peutic agents toxicity; both usually accompanied with se-
vere side effect on non-target cells. Certainly, there is an
unmet need for development or exploration of alterna-
tive and complementary treatment options. Based on ex-
tensive literature search, it could be opined that the use
of monotherapy and surgery, as often the case, might
not be exhaustive and efficacious treatment for cancer.
Consequently, an important area researchers and clini-
cians should focus SCCHN investigations into is the ap-
plication of phytopharmacology in managing, curing or
ameliorating treatment-induced toxic effects.
Medicinal plants are made up of various chemical con-
stitutes that works independently, supplement or in syn-
ergy to improve health [3]. These natural plant-derived
medicines that have been used in the remedy of various
health problems, have a safe profile, they are gentle,
cost-effective and easily accessible; and this has encour-
aged self-medication without consulting a medical prac-
titioner [33–36].
While the exact molecular mechanisms by which medi-
cinal plants mediate their chemo-preventive (cancer pre-
ventive) properties are still unclear, it has been suggested
that the mechanism of medicinal plant-derived chemo-
prevention may be due to the presence of phytocom-
pounds (which may work in a synergistic/combinatorial
manner) with strong antioxidant and antiproliferative
properties [37]. Similarly, it has been reported that the
chemical constituents of medicinal plants can induce
apoptosis, possess anti-inflammatory, anti-hormonal and
immune-enhancing effect. They can also induce cell cycle
arrest, cell differentiation, suppression of cellular prolifera-
tion and angiogenesis; as well as inhibiting secondary
modification and development of the neoplastic cells [38].
It has been suggested that phytocompounds can carry
out their antioxidant activities by lowering free radical
production through metal chelation and free radical
scavenging [22, 39]. In addition, phytocompounds can
reduce mitochondrial damage and fission, thereby en-
hancing the electron transport chain and oxidative phos-
phorylation [39]. The transcription factor nuclear
erythroid 2-related factor 2 (Nrf2) can be activated and
translocated to the nucleus, by polyphenols (e.g., hydro-
xytyrosol), where it can transactivate antioxidant en-
zymes and phase II genes, by binding antioxidant
response elements promoters [38, 39]. Anti-
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inflammatory effect of phytocompounds have been
linked to downmodulation of proinflammatory cyto-
kines, prostaglandins, NF-κB, nitric oxides, as well as in-
ducible NO synthase (iNOS) and other pro-
inflammatory genes [39]. Furthermore, hydroxytyrosol
has been found to influence cellular energetics by in-
creasing the expression of respiratory chain mitochon-
drial complexes (I-V) and overall mitochondrial function
[39].
Plant-derived anticancer agents
For centuries now, plants have been recognized in the
treatment of cancer. More so, several bioactive com-
pounds isolated from plants are presently undergoing
clinical trials or preclinical trials for cancer [5–7, 9]. Im-
peratively, present and future studies are expected to ex-
plore phytomedicine preparations to offer proper
treatment and management of various forms of cancers.
In this context, we have reviewed some phytomedicinal
drugs and compounds that have shown remarkable ac-
tivities against SCCHN.
Herbal-derived drugs with anti-cancer properties
Vinca alkaloids (VA) are important anticancer drugs ob-
tained from the Madagascar periwinkle plant [40]. Cur-
rently, the four main semi-synthetic derivatives of VA in
use against cancer are vinorelbine, vindesine, vinfosiltine
and vinovelbine, they are used alone or complementing
other phytochemical compounds to fight a large number
of cancers [41]. As documented by Safarzadeh et al. [42],
the mechanism VA uses in exacting their anti-cancer ef-
fect is by the disruption of microtubule function through
tubulin interaction and destruction resulting to arrest
and termination of cell division. Regimens able to im-
pede the microtubule assembly can arrest cell cycle at
metaphase, hence leading to cell death via apoptosis
[43]. Added to their anti-cancer properties, VA has been
used in the treatment of high blood pressure [40] and
diabetes [44]. On the basis of the promising activities
shown by vinorelbine in head and neck cancer, Gebbia
et al., [45] tested its activity in combination with cis-
platin. It was shown that the combination is effective
both in patients of recurrent and untreated unresectable
patients. When co-administered with cisplatin and 5-
fluorouracil, vinorelbine has shown complete responses
in SCCHN [46]. Another study using vinblastine com-
bined with monoclonal anti-flk-1 (DC101) in the treat-
ment of poor prognosis-related human neuroblastoma
cells, grown in Severe combined immunodeficiency
(SCID) mice showed that low doses of vinblastine com-
bined with DC101 achieved full and sustained regression
of established cancer, without subsequent host toxicity
[47].
Berberine (BBR), a natural isoquinoline quaternary al-
kaloid is well known for its immense application in the
remedy of various maladies in the traditional ayurvedic
literature [48]. Based on this, researchers have explored
the cytotoxic activities of this compound against cancer.
In hepatocellular carcinoma cells, BBR causes cancer cell
death by simultaneous induction of autophagy and apop-
tosis [49]. BBR caused an increase in Bax expression and
a decrease in mitochondrial membrane permeability,
leading to mitochondrial apoptosis in MHCC97-L and
HepG2 cells [49]. Accumulative evidence using this iso-
quinoline alkaloid has demonstrated its potential appli-
cation as a chemotherapeutic agent for the management
of SCCHN. For example, in an in vitro study using hu-
man tongue cancer SCC-4 cell line, it was shown that
BBR stimulated the expression of Apaf-1 which resulted
to increased activation of caspase-3, hence causing apop-
tosis [50]. More recently, another work was done on
FaDu head and neck squamous cell carcinoma cells,
demonstrated that BBR triggered upregulation of apop-
totic ligands like Tumour Necrosis Factor (TNF)- related
apoptosis-inducing ligand and FasL, activated caspase-8,-
7 and − 3 and adenosine diphosphate (ADP) ribose poly-
merase [51]. Still, in the same context, inhibition of the
migration and invasion of human SCC-4 tongue squa-
mous carcinoma cells by BBR was reported by Ho et al.,
2009b. In the study [52], the inhibition of Matrix Metal-
loproteinase (MMP)-2 and − 9 in human SSC-4 cells was
mediated by thep-JNK, p-ERK, p-p38, IkK and NF-kB
signalling pathways. Remarkably, BBR anti-cancer effect
increased significantly when co-administered with evo-
diamine [53], arsenic trioxide [54] and cisplatin [55].
Another vital addition to the plant-derived anti-cancer
drug armamentarium is the taxanes. Currently consid-
ered as the most efficacious anti-cancer agent, taxanes
act by interfering with the microtubules and has a cru-
cial role in cell division [41, 42]. Paclitaxel (taxol) is uti-
lized as therapeutic agent in ovarian, Kaposi Sarcoma,
lung cancer, SCCHN and breast cancer [56]. Studies
have targeted molecular treatment against epidermal
growth factor receptor (EGFR) since it has shown to be
promising in adjuvant therapy for head and neck cancer.
The therapeutic efficacy of EGFR blockage with pacli-
taxel combined with PKI166 against human oral cancer
increased programmed cell death in vitro and growing
orthotopically in nude mice [57]. Also, administration
with cisplatin and fluorouracil causes significant survival
benefits with tolerable toxicity for patients with locally
advanced head and neck cancer [58].
Herbal-derived compounds with anti-cancer activities
Upregulation of both proinflammatory and proangio-
genic factors are implicated in aggressive tumour growth
and decline in the health of sufferers of SCCHN.
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Curcumin; a phenolic compound derived from rhi-
zome is a potent inhibitor of cell proliferation and in-
ducer of programmed cell death in SCCHN by
downregulating IκBα kinase (IKK) mediated NF-Kβ acti-
vation [59, 60]. Moreover, the cytotoxic effects of doxo-
rubicin and its analogues involve NF-Kβ signalling
pathway, therefore, curcumin increases the efficacy of
doxorubicin by impeding NF-Kβ signalling pathway [42].
More recently, grape seeds proanthocyanidins (GSPs)
has been gaining interest as an anti-SCCHN agent. GSPs
has the ability to hinder the SCCHN cell invasion by tar-
geting the EGFR expression, as well as halting the transi-
tion from epithelial to mesenchymal cells [61]. This
polyphenolic compound prevents cancer initiation with
no toxicity in animal models and normal human bron-
chial epithelial cells [62, 63].
Park et al., [64] studied Licochalcone-A purified from
Glycyrrhiza inflata roots and found out that it signifi-
cantly increased death of pharyngeal squamous carcin-
oma FaDu cells with activated apoptotic factors and Poly
(ADP-ribose) polymerase (PARP) in a caspase-
dependent manner and decreased anti-apoptotic factors.
Lee et al. (2008) [65] and Cho et al. (2014) [66] have also
lent credence to cytotoxic activity of Licochalcone-A.
Similarly, resveratrol, a phytoalexin found in red grape
skin, has been shown to cause cancer cell death via dif-
ferent mechanisms such as mitotic catastrophe, apop-
tosis and autophagy [67].
Overall, the scope of phytopharmacology in the treat-
ment and management of cancer is imminent and could
not be undermined. In fact, when employed for SCCHN
therapy, phytopharmacology has great potentials in min-
imizing side effects caused by chemoradiotherapy and
surgery, at the same time increasing survival rates and
reducing recurrence/ unresectable cancer rates. Al-
though there are still many questions to be answered in
the field of phytomedicine, such as efficacy and safety
parameters of herbal products, the use of plant products
in head and neck cancer treatment holds promising
grounds and warrants continuous research adventures.
A list of selected compounds of pharmacological signifi-
cance in head and neck cancer is presented in Table 1.
Phytopharmacology and structural biology
The understanding of the structure and function of pro-
teins is an important phenomenon in deciphering the
molecular basis of diseases. Hence, structural biology is
a research field of study that focuses on determining the
function, molecular mechanisms and structure of bio-
logical molecules or proteins. The field has aided the un-
derstanding of basic molecular mechanisms in diseases
such as designing of new pharmaceutical products, as
well as understand drug action [68, 69]. Thus, structural
phytopharmacology is an approach used in designing
and developing novel drugs to target and inhibit proteins
or biological molecules through the means of medicinal
plants and their products.
Cost and unavailability of orthodox drugs and health
care, as well as several side effects associated with the
use of synthetic drugs, makes using phytocompounds a
potentially valuable and practical options [70]. There-
fore, the exploration of pharmacologically active sub-
stances found in plants has been a better alternative in
medical applications, this is due to the presence of sev-
eral complex chemical substances of diverse composition
which are found as secondary metabolites (phytonutri-
ents or phytochemicals) such as flavonoids, terpenoids,
alkaloids, saponins, polyphenols, lignans, carotenoids, in-
doles, isoflavones among others [71]. Globally, functional
bioactive compounds (FBCs) of plants source or plant-
derived compounds have been significant sources of
therapeutic drugs for humans and animals in treatment
Table 1 Selected phytocompounds of therapeutic importance against head and neck cancer
Phytocompound Mechanism of action reference
Vinca alkaloids Disrupts microtubule function through tubulin interaction and destruction resulting
Stalls cell division and facilitate apoptosis
[42]
[43]
Berberine cancer cell death by simultaneous induction of autophagy and apoptosis
caused an increase in Bax expression and a decrease in mitochondrial membrane permeability, leading to
mitochondrial apoptosis
[49]
Taxanes Interferes with the microtubules and cell division
Blocks epidermal growth factor receptor (EGFR)
[41, 42]
[57]
Curcumin Potent inhibitor of cell proliferation and inducer of programmed cell death in SCCHN by downregulating




Has the ability to hinder the SCCHN cell invasion by targeting the EGFR expression, as well as halting the
transition from epithelial to mesenchymal cells
[61]
Licochalcone-A Significantly increased death of pharyngeal squamous carcinoma FaDu cells with activated apoptotic
factors and PARP in a caspase-dependent manner and decreased anti-apoptotic factors
[64–66]
Resveratrol Cause cancer cell death via mitotic catastrophe, apoptosis and autophagy [67]
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of diverse diseases [72]. FBCs possess numerous chem-
ical and structural properties such as the ability to inter-
act or binds and stimulate a specific molecular receptor
or protein and this has led to several important discover-
ies. For instance, gingerol, resveratrol, phytosterol, epi-
gallocatechin, myricetin, among others may directly
influence several molecular signal transduction pathways
such as cell migration/proliferation, metabolic disorders,
inflammation cascade, and oxidative stress which are im-
plicated in the development of different non-
communicable diseases [73–75], such as cancer.
An overview of phytochemical interactions and
stimulations of molecular receptors
Plant-based drugs have been elucidated with thera-
peutic activity in the treatment of diverse diseases due
to their ability to stimulate or interact with biological
molecules or proteins which are responsible for such
diseases. Example of such plant-based drugs approved
for therapeutic use in the treatment of diseases are ar-
temisinin (Artemisia annuaI), arglabin (Artemisia gla-
bella Kar. and Kir), capsaicin (Capsicum annum),
colchicine (Colchicum spp), cannabidol dronabinol
(Cannabis sativa). Others are Solamargine (Solanum
spp), masoprocol (Larrea tridentata), galanthamine
(Galanthus caucasicus), paclitaxel (Taxus brevifolia),
ingenol mebutate (Euphorbia peplus), omacetaxine
mepesuccinate (Cephalotaxus harringtonia).
In 2011, Yang et al., [76] investigated the apoptotic
mechanisms of celastrol, a major biologically active com-
pound isolated from Tripterygium regelii on human
breast cancer cells line (MCF-7). It was shown that
celastrol inhibited cell growth remarkable in time- and
dose-dependent manners. It was further discovered that
the compound induced the formation of apoptotic bod-
ies, accumulation of sub-G1 deoxyribonucleic acid
(DNA), and condensation of nuclear in MCF-7 cells
[76]. Also, celastrol stimulated the activation of caspase-
7, − 8 and − 9, and upregulated the activation of caspase
family proteins, cleavage of PARP, release of cytochrome
c and AIF, and mediated the cleavage of caspase-8. More
so, it was revealed that celastrol increased the upregula-
tion of pro-apoptotic Bax protein and downregulated the
expression of the anti-apoptotic Bcl-2 protein. All these
aforementioned activities of celastrol depict its inhibitory
role in the proliferation of human breast cancer cells
[76]. In 2016, Pan and co-workers [77] evaluated the
phytopharmacological activities of triptonide, a com-
pound derived from Tripterygium wilfordii on telomer-
ase reverse transcriptase (TERT) protein, an enzyme
responsible for the malignant progression and
immortalization of acute myeloid leukemia (AML) and
HPV-induced oral cancers. It was observed in their
mechanistic studies that the derived compound totally
induces senescence by suppressing the transcription of
TERT which resulted in apoptosis in cultured AML cell
lines (U937 and HL-60 AML), and inhibited colony for-
mation as well as the growth of leukemia by suppressing
oncogenic c-Myc. Also, the compound promotes the
proapoptotic gene which encodes for DNA damage-
inducible transcript 3 and stimulates the transcription of
genes (p16 and p21) which are senescence-promoting
gene. In addition, it was shown that triptonide com-
pletely suppressed the formation of human leukemia cell
without posing any observable toxicity effects in mice in
a xenograft model [77].
In another related study by Tan and colleagues [78],
the identification and inhibitory activities of 56 novel
naturally occurring phytochemicals were investigated on
the efflux transporter breast cancer resistance protein
(ABCG2/BCRP); a multidrug resistance protein in breast
cancer. In the study, the results of non-flavonoid phyto-
chemicals investigated (ellagic acid, berberine, oleanolic
acid, celastrol, ursolic, limonin and sinapic acid) showed
significant increase in inhibitory activities of the phyto-
chemicals compounds on ABCG2-mediated transport
enzyme in membrane- and cell-based transport inhib-
ition analyses. Other novel flavonoid phytochemical
compounds identified to inhibit ABCG2 protein in the
study were myricetin, pinocembrin, chrysoeriol, querci-
trin, laricitrin, tamarixetin, 3′,4′,5′-trimethylether, trice-
tin 3′,4′,5′-trimethylether and tricetin. Thus, the
inhibitory activities of these phytochemical compounds
on ABCG2 propose a background for further examin-
ation of ABCG2-modulated phytochemical bioavailabil-
ity and multidrug resistance in breast cancer [78]. In a
similar study in 2013, Perez and colleagues [79] investi-
gated the inhibitory effects of daidzein and genistein,
isoflavones found in soy on ABCG2 by reducing the
plasma and milk levels of danofloxacin in sheep. It was
observed that both isoflavones effectively inhibited the
in vitro movement of the drug in BCRP-transduced
MDCK-II cells. This predicted that the soy-enriched diet
can modify the in vivo milk secretion of danofloxacin, a
BCRP substrate in sheep [79].
A study by Biswas and co-workers [80], evaluated the
inhibitory activities of phytochemical compounds on
multidrug resistance in cancer and proposed the mecha-
nisms by which standardized berry extracts inhibit the
endothelial cell tumour growth for hemangiomas. The
study further established that natural berry extracts con-
siderably inhibited the actions of multidrug resistance
protein-1 (MRP-1) in EOMA cells when compared with
controls. The inhibition of MRP-1 resulted in apoptotic
tumour cell death via the accumulation of oxidized
glutathione (GSSG) in the nucleus of EOMA cells where
there is hyperactiveness of NADPH oxidase thereby
causing angiogenesis pathology [80].
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Role of computational biology in phytopharmacology
In recent time, computational biology has given
insight to target proteins which are functionally and
structurally conserved in diseases using medicinal
plant phytochemicals. This is due to higher cost and
time involved in conventional methods of screening
for new drugs and new chemical entities (NCEs) with
low toxicity and high pharmacological response. In
2019, Oyinloye and co-workers [81] employed this ap-
proach in proposing the regulation of glucose con-
sumption by cancerous cells via the inhibition of
glucose transporter-4-protein (GLUT4) by selected
phytochemical compounds from Solanum xanthocar-
pum. Their study revealed that out of seven phyto-
chemical compounds selected from Solanum
xanthocarpum, stigmasterol glucoside showed higher
binding affinity to GLUT4 when compared to the
control. Also, stigmasterol glucoside fulfils oral drug-
ability of rule of five and conversely predicted to be
non-mutagen and safe for the body. Added to this,
computational biology has also been used in screening
for potent pan-serotype phytochemical compounds as
inhibitors for conserved non-structural dengue virus
protein targets (NS1, NS2B/NS3 and NS5) [82], as
well as the molecular mechanism and pharmacothera-
peutics activity of phytocompounds against breast
cancer drug-protein target (aromatase) [83].
Conclusion
The use of medicinal plants in the treatment of diseases
(ethnomedicine) is an ancient tradition that has co-
existed with human habitation [84]. Overall, several phy-
tocompounds have been demonstrated to be of thera-
peutic importance, but fewer numbers have been
brought into clinical dental utility (Fig. 1). Persistent rise
in the incidence of oral cancer has long been recognised
as a major public health problem worldwide [85], and lo-
cally in Africa [16]. Phyto-constituents derived from me-
dicinal plants have proven to be an important source of
therapeutically useful compounds with the potential of
being developed into new and potent pharmaceuticals
[85]. Phyto-dentistry, the use of plants and their prod-
ucts in dental practice has long been documented, how-
ever, plant products have only been marginally used in
dental material, as well as an adjunct therapy in dental
practice [84]. Emerging omics fields and development of
state-of-the-art omics instrumentation is expected to ac-
celerate the uptake and application of phytodentistry to
treating head and neck cancers, and indeed other dental
diseases. Hence, this review heralds a wider coverage of
phytodentistry for improved, personalized and cost-
effective treatment of dental diseases in Africa.
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